Elevated serum sorbitol and not fructose in type 2 diabetic patients

Biomarker Insights

Volumn 2010, Issue 5, 2010, Pages 33-38

  Preston, Gregory M ^a   Calle, Roberto A ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Diabetic complications; Fructose; Polyol pathway; Sorbitol

Indexed keywords

ALDEHYDE REDUCTASE; FRUCTOSE; ORAL ANTIDIABETIC AGENT; SORBITOL;

ACCURACY; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; ETHNICITY; FEEDING; FEMALE; GLUCOSE BLOOD LEVEL; HEART RATE; HUMAN; MALE; MASS FRAGMENTOGRAPHY; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; SYSTOLIC BLOOD PRESSURE;

EID: 77952305136     PISSN: None     EISSN: 11772719     Source Type: Journal    
DOI: 10.4137/bmi.s4530     Document Type: Article

References (24)

1. Resnick HE, Foster GL, Bardsley J, Ratner RE. Achievement of American Diabetes Association clinical practice recommendations among U.S. adults with diabetes, 1999-2002: the National Healthy and Nutrition Examination Survey. Diabetes Care. 2006;29:531-7.
2. Oates PJ. Polyol pathway and diabetic peripheral neuropathy. Int Rev Neurobiol. 2002;50:325-92.
3. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes. 2005;54:1615-25.
4. Barnett PA, Gonzalez RG, Chylack LT Jr, Cheng HM. The effect of oxidation on sorbitol pathway kinetics. Diabetes. 1986;35:426-32.
5. Ido Y. Pyridine nucleotide redox abnormalities in diabetes. Antioxid Redox Signal. 2007;9:931-42.
6. Beyer-Mears A, Murray FT, Cruz E, Rountree J, Sciadini M. Comparison of sorbinil and ponalrestat (Statil) diminution of proteinuria in the BB rat. Pharmacology. 1992;45:285-91.
7. Tilton RG, Cheng K, Nyengaard JR, et al. Inhibition of sorbitol dehydrogenase: effects on vascular and neural dysfunction in streptozocin-induced diabetic rats. Diabetes. 1995;44:234-42.
8. Schmidt RE, Dorsey DA, Beaudet LN, et al. A potent sorbitol dehydrogenase inhibitor exacerbates sympathetic antonomic neuropathy in rats with streptozocin-induced diabetes. Exp Neurol. 2005;192:407-19.
9. Matasumoto T, Ono Y, Kurono M, Kuromiya A, Nakamura K, Bril V. Improvement of motor nerve conduction velocity in diabetic rats requires normalization of the polyol pathway metabolites flux. J Pharmacol Sci. 2009;109:203-10.
10. Green DA, Arezzo JC, Brown MB, the Zenarestat Study Group. Effect of aldose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy. Neurology. 1999;53:580-91.
11. Hotta N, Toyota T, Matsuoka K, et al. Clinical efficacy of fidarestat, a novel aldose reductase inhibitor, for diabetic neuropathy: a 52-week multicenter placebo-controlled double-blind parallel group study. Diabetes Care. 2001;24:1776-82.
12. Brill V, Buchanan RA, the AS-3201 Study Group. Aldose reductase inhibition by AS-3201 in sural nerve from patients with diabetic sensorimotor polyneuropathy. Diabetes Care. 2004;27:2369-375.
13. Oates PJ, Klioze SS, Schwartz PF, Boland AD, the Zopolrestat Diabetic Nephropathy Study Group. Aldose reductase inhibitor zopolrestat reduces elevated urinary albumin excretion rate in type 1 diabetes mellitus subjects with incipient diabetic nephropathy. J Am Soc Nephrol. 2008;19:642A.
14. Asano T, Saito Y, Kawakami M, Yamada N, Fidarestat Clinical Pharmacology Study Group. Fidarestat (SNK-860), a potent aldose reductase inhibitor, normalizes the elevated sorbitol accumulation in erythrocytes of diabetic patients. J Diabetes Complications. 2002;16:133-8.
15. Asano T, Saito Y, Kawakami M, Yamada N, Sekino H, Hasegawa S, Fidarestat Clinical Pharmacology Study Group. Erythrocytic sorbitol contents in diabetic patients correlate with blood aldose reductase protein contents and plasma glucose levels, and are normalized by the potent aldose reductase inhibitor fidarestat (SNK-860). J Diabetes Complications. 2004;18:336-42.
16. Ando H, Takamura T, Nagai Y, Kaneko S, the Kanazawa University Multicenter Diabetes Study Group Erythrocyte sorbitol level as a predictor of the efficacy of epalrestat treatment for diabetic peripheral polyneuropathy. J Diabetes Complications. 2006;20:367-70.
17. Reddy GB, Satyanarayana A, Balakrishna N, et al. Erythrocyte aldose reductase activity and sorbitol levels in diabetic retinopathy. Mol Vision. 2008;14:593-601.
18. Kawasaki T, Akanuma H, Yamanouchi T. Increased fructose concentrations in blood and urine in patients with diabetes. Diabetes Care. 2002;25:353-7.
19. Kawasaki T, Ogata N, Akanuma H, et al. Postprandial plasma fructose level is associated with retinopathy in patients with type 2 diabetes. Metabolism. 2004;53:583-8.
20. 2]-D-glucose-enriched plasma samples by gas chromatography-mass spectrometry. J Chromatogr. 1991;572:302-6.
21. Malone JI, Knox G, Benford S, Tedesco TA. Red cell sorbitol, an indicator of diabetic control. Diabetes. 1980;29:861-4.
22. Kwang-Hyok S, Ui-Nam P, Sarkar C, Bhadra R. A sensitive assay of red cell sorbitol by high performance liquid chromatography: potential for diagnostic evaluation of diabetes. Clinica Chimica Acta. 2005;354:41-7.
23. Comazzi S, Bertazzolo W, Bonfanti U, Spagnolo V, Sartorelli P. Advanced glycation end products and sorbitol in blood from differently compensated diabetic dogs. Res Vet Sci. 2008;84:341-6.
24. Landau Z, Novotny MJ, Preston GM, et al. Pharmacokinetics, pharmacodynamics, tolerability, and safety of a novel sorbitol dehydrogenase inhibitor in healthy participants. J Clin Pharmacol. 2010;50:521-30.